We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Tumor-Initiating Cell Probe makes it Possible to Simultaneously Diagnose and Treat Cancer

By HospiMedica International staff writers
Posted on 05 Apr 2023

Effective prevention measures and timely diagnosis, followed by prompt intervention through effective treatment are crucial in managing cancer. More...

However, the feasibility of providing prompt treatment upon diagnosis remains questionable. Now, researchers have successfully determined the ability of fluorescent probe for tumor-initiating cell yellow (TiY) to stain the cells responsible for tumor growth as well as suppress the growth of those cells at the same time. This promising development offers a single-step solution to both diagnose and treat cancer. Current cancer treatments often fail to completely remove tumors due to metastasis or recurrence, but TiY presents a hopeful approach to overcoming this challenge.

In their previous study, the research team at Pohang University of Science and Technology (POSTECH, Gyeongbuk. Korea), had developed a fluorescent probe called TiY that could selectively identify and detect tumor-initiating cells (TICs), similar to a fluorescent highlighter. Expanding on this achievement, the team conducted further research to investigate TiY's potential for cancer treatment. In the current study, the team examined changes in cancer stem cells in response to varying concentrations of TiY. The team obtained cancer stem cells from patients with lung cancer and transplanted them into mice for experimental purposes. To assess the therapeutic effects of TiY staining, the team gradually increased the dosage of TiY administered to the mice via intravenous injection during their experiments.

The researchers found that at low concentrations, TiY could stain cancer stem cells, but at higher concentrations, it demonstrated an impressive ability to inhibit their growth, resulting in significant destruction of the cancer stem cells. This targeted treatment is facilitated by TiY's unique mechanism, which enables its molecules to selectively bind to vimentin, a muscle-specific protein found in the cytoskeleton of cancer stem cells, thereby enabling TiY to specifically target and suppress these cells.

Related Links:
POSTECH
A*STAR


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
New
Anesthetic Gas Measurement Module
Scio Four
New
Hospital Stretcher
Millennium 5
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The engine-free, nonlinear, flexible, micro-robotic platform leverages AI to optimize GBM treatment (Photo courtesy of Symphony Robotics)

First-Ever MRI-Steerable Micro-Robotics to Revolutionize Glioblastoma Treatment

Glioblastoma Multiforme (GBM) is one of the most aggressive and difficult-to-treat brain cancers. Traditional surgical procedures, such as craniotomies, involve significant invasiveness, requiring large... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.